Project Details
Description
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study of the Safety, Tolerability, and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMVseropositive (R+)
| Status | Finished |
|---|---|
| Effective start/end date | 7/15/13 → 12/31/20 |
Funding
- CHIMERIX, INC.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.